Telomere Attrition in Human Lens Epithelial Cells Associated with Oxidative Stress Provide a New Therapeutic Target for the Treatment, Dissolving and Prevention of Cataract with N-Acetylcarnosine Lubricant Eye Drops. Kinetic, Pharmacological and Activity-Dependent Separation of Therapeutic Targeting: Transcorneal Penetration and Delivery of L-Carnosine in the Aqueous Humor and Hormone-Like Hypothalamic Antiaging Effects of the Instilled Ophthalmic Drug Through a Safe Eye Medication Technique.

What It Covers

This review looks at Carnosine.

It has been hypothesized that senile cataract may serve as a marker for generalised tissue aging, since structural changes occurring in the proteins of the lens during cataract formation are similar to those which occur elsewhere as part of the aging process.

The published analysis revealed a strong age-dependent relationship between undergoing cataract surgery and subsequent mortality.

How the Review Was Done

The lens opacity status is considered as an independent predictor of 2-year mortality, an association that could not be explained by potential confounders.

Telomeres have become important biomarkers for aging as well as for oxidative stress-related disease.

The lens epithelium is especially vulnerable to oxidative stress.

Oxidative damage to the cuboidal epithelial cells on the anterior surface of the lens mediated by reactive oxygen species and phospholipid hydroperoxides can precede and contribute to human lens cataract formation.

The erosion and shortening of telomeres in human lens epithelial cells in the lack of telomerase activity has been recognized as a primary cause of premature lens senescence phenotype that trigger human cataractogenesis.

What Was Measured

PubMed files the paper under topics including Administration, Ophthalmic, Age Factors, Aging, Antioxidants, Carnosine, Cataract and Cornea.

What This Means in Plain Language

This is a review of Carnosine.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Recent patents on drug delivery & formulation), a journal based in United Arab Emirates.

More context: the Carnosine compound page, all human trials.